yohimbine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
3659 146-48-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • yohimbine
  • yohimbin
  • quebrachin
  • quebrachine
  • yohimbine hydrochloride
  • yohimbine HCl
A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.
  • Molecular weight: 354.45
  • Formula: C21H26N2O3
  • CLOGP: 2.17
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 65.56
  • ALOGS: -3.01
  • ROTB: 2

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 33 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.48 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 14.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.20 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04BE04 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs used in erectile dysfunction
CHEBI has role CHEBI:37890 alpha-adrenergic receptor blockaders
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:131787 D2R antagonist
MeSH PA D018663 Adrenergic Agents
MeSH PA D058669 Adrenergic alpha-2 Receptor Antagonists
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D009184 Mydriatics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D064804 Urological Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Impotence off-label use 397803000
Hypocupremia contraindication 19577007
Depressive disorder contraindication 35489007
Low blood pressure contraindication 45007003
Heart disease contraindication 56265001 DOID:114
Kidney disease contraindication 90708001 DOID:557
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Psychiatric Disturbance contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

ProductApplicantIngredients
Yobine Injection Akorn Animal Health Inc. 1
Antagonil Wildlife Laboratories Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.2 acidic
pKa2 7.31 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2B adrenergic receptor GPCR ANTAGONIST Ki 8.70 CHEMBL IUPHAR
Alpha-2A adrenergic receptor GPCR ANTAGONIST Ki 9.38 CHEMBL IUPHAR
Alpha-2C adrenergic receptor GPCR ANTAGONIST Ki 9.30 CHEMBL IUPHAR
5-hydroxytryptamine receptor 1A GPCR ANTAGONIST Ki 7.30 IUPHAR
5-hydroxytryptamine receptor 2B GPCR ANTAGONIST Ki 7.90 IUPHAR
5-hydroxytryptamine receptor 6 GPCR Ki 6.11 DRUG MATRIX
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 5.60 IUPHAR
Alpha-1A adrenergic receptor GPCR Kd 6.40 CHEMBL
D(3) dopamine receptor GPCR Ki 5.60 PDSP
5-hydroxytryptamine receptor 1B GPCR ANTAGONIST Ki 7.60 IUPHAR
5-hydroxytryptamine receptor 1D GPCR ANTAGONIST Ki 7.70 IUPHAR
Cytochrome P450 2D6 Enzyme IC50 5.69 DRUG MATRIX
Adenosine receptor A3 GPCR IC50 7.02 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 8.80 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 8.96 CHEMBL
5-hydroxytryptamine receptor 5A GPCR ANTAGONIST Ki 5.30 IUPHAR
5-hydroxytryptamine receptor 1F GPCR ANTAGONIST Ki 7 IUPHAR
5-hydroxytryptamine receptor 1E GPCR ANTAGONIST Ki 5.90 IUPHAR
DNA topoisomerase 1 Enzyme IC50 4.52 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 4.48 CHEMBL
Dual specificity phosphatase Cdc25A Enzyme IC50 4.65 CHEMBL
D(2) dopamine receptor GPCR Ki 6.16 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 6.18 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 5.91 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 8.70 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 7.28 CHEMBL
D(2) dopamine receptor GPCR IC50 5.95 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 6.90 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 5.79 CHEMBL
5-hydroxytryptamine receptor 2B GPCR ANTAGONIST Ki 7.30 IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel Ki 7.35 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 8.44 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 7.31 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 9.22 CHEMBL
Dopamine receptor GPCR Ki 5.70 CHEMBL
Alpha-2 adrenergic receptor GPCR Ki 9.22 CHEMBL
5-hydroxytryptamine receptor 1B GPCR ANTAGONIST Ki 8.30 IUPHAR
5-hydroxytryptamine receptor 5A GPCR ANTAGONIST Ki 6 IUPHAR
Alpha-2A adrenergic receptor GPCR Ki 8.36 CHEMBL
5-hydroxytryptamine receptor 1F GPCR ANTAGONIST IC50 6.20 IUPHAR
D(3) dopamine receptor GPCR Ki 5.61 CHEMBL

External reference:

IDSource
4022649 VUID
N0000020654 NUI
D06671 KEGG_DRUG
65-19-0 SECONDARY_CAS_RN
4018920 VANDF
4022649 VANDF
C0724441 UMLSCUI
CHEBI:10093 CHEBI
CHEMBL15245 ChEMBL_ID
DB01392 DRUGBANK_ID
D015016 MESH_DESCRIPTOR_UI
8969 PUBCHEM_CID
102 IUPHAR_LIGAND_ID
2Y49VWD90Q UNII
133041 RXNORM
1391 MMSL
5700 MMSL
7315 MMSL
7316 MMSL
d01386 MMSL
002414 NDDF
003550 NDDF
398674007 SNOMEDCT_US
73407000 SNOMEDCT_US
96264005 SNOMEDCT_US
CHEMBL537669 ChEMBL_ID

Pharmaceutical products:

None